MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss ...
Evidence from multiple model systems supports a shift away from heme transport and toward metabolic dysfunction and oxidative stress as key drivers of TANGO2 deficiency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback